12-11-2022 | IgA Vasculitis | Review Article
Cutaneous vasculitis associated with molecular tergeted therapies: systematic review of the literature
Published in: Clinical Rheumatology | Issue 2/2023
Login to get accessAbstract
Key Points
• It should be kept in mind that targeted therapies can lead to CV with or without systemic signs, which sometimes withholds their uses.
• Since targeted therapies are often used in the treatment of autoimmune and inflammatory diseases, CV associated with targeted therapies is difficult to recognize, and it is often mistakenly attributed to the underlying disease.
• Although the pathogenesis of CV associated with targeted therapies is not fully understood, there are several proposed mechanisms.
• Corticosteroids are the mainstay of treatment after discontinuation of the offending targeted agent.
|